Opinion

Aug 29, 2025, 15:06

Jason Binder: Precision Access or Pay-to-Play?

Jason Binder, Head of Patient Experience at Pathos, shared on LinkedIn:

“Precision Access or Pay-to-Play?

GBM families are chasing science-backed options abroad. But in Germany, access may mean a regulated compassionate use program or a pay-to-play named-patient route with no protections.

New post on BrainStorm Health.”

Jason Binder

More posts featuring GBM.

BrainStorm Health cancer GBM Jason Binder OncoDaily Oncology Precision Access

Why Is Financial Wellness Crucial for Physicians and Health Care Professionals?

BOT/BAL Advancements, BATTMAN Trial, FDA Approval Challenges and Key Highlights from Agenus Stakeholder Briefing

10 Leading Experts Join OncoDaily Journal Editorial Team

Top 10 Oncogrants of the Week: Fueling Cancer Research and Innovation

Soon-Shiong’s “Bioshield” Sparks Early Promise in Recurrent GBM, With 2 Near-CRs and 100% Disease Control

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023